A Longitudinal Study of COVID-19 Sequelae and Immunity

Study Description:

This is a longitudinal cohort study to evaluate the clinical sequelae of acute COVID-19 and characterize the immune response to SARS-CoV-2. Household contacts of the COVID-19 cohort will also be recruited and serve as a control group.

Objectives:

• Characterize the medical sequalae and persistent symptoms following recovery from COVID-19 in a cohort of disease survivors.
• Estimate the incidence and risk factors for post-COVID-19 medical sequalae.
• Characterize antibody and cell-mediated immune responses to SARS-CoV- 2 in disease survivors
• Characterize evolution of the antibody and T cell-mediated responses to SARS-CoV-2 in survivors over time
• Evaluate survivors for evidence of re-infection with future waves of COVID-19 to determine if initial infection confers long-term protective immunity
• Determine the incidence of clinically silent infection in household contacts
• Characterize the mental health status of survivors and controls including medical trauma related sequelae

Endpoint:

Establish a clinically well characterized cohort of persons recovered from COVID-19 and close contacts of persons with COVID-19

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, all individuals must meet all of the following criteria:

• Stated willingness to comply with all study procedures and availability for the duration of the study
• Age 18 years or older.
• Ability of participant to understand and the willingness to sign a written informed consent document.
• Hemoglobin of 9.0 gm/dl or higher
• Willingness to give consent for the storage of blood samples for research.
• Have a physician or clinic outside NIH to manage underlying medical conditions or agreeing to establish care with an outside physician or clinic for any medical conditions requiring treatment that may be diagnosed as a result of protocol participation.

COVID-19 Survivor Group

• Documented prior COVID-19 as evidenced by:

• detection of SARS-CoV-2 RNA or antigen in nasopharyngeal swab, sputum or other sample source with EUA/approval from the FDA; or
• a positive antibody test using an assay that has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and a history clinical manifestation compatible with COVID-19.
• Greater than 6 weeks since onset of COVID-19 symptoms and no fever for at least 1 week. For individuals with asymptomatic infection, screening will not occur until at least 4 weeks after the last positive SARS-CoV-2 PCR or antigen test.

COVID-19 Close Contact

• Living in the same household as a COVID-19 survivor during the time of illness or, being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time or having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on).
• No diagnosis of COVID-19 or current symptoms suggestive of COVID-19

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

• Current abuse of alcohol or other drugs that, in the judgement of the Principal Investigator (PI) could interfere with patient compliance.
• Inability to travel to the NIH Clinical Center for study visits
• Any medical or mental health condition that, in the judgement of the PI, would make the volunteer unable to participate in the study.
• Positive SARS-CoV-2 PCR at screening visit
• Positive test for antibodies to SARS-CoV-2 nucleocapsid protein at the screening visit (control group only).
• History of any of the following in the past 14 days: fever > 38.2 degrees Celsius; new or worsening respiratory symptoms (e.g. cough, dyspnea).
• Pregnancy